JohnDwyerPowderlyIIMD
Oncology • Huntersville, NCAssistant Consulting Professor in the Department of Medicine, Duke University School of Medicine
Are you Dr. Powderly?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 66 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
9801 Kincey Ave
Suite 145
Huntersville, NC 28078Phone+1 704-947-6599Fax+1 704-947-6597
Summary
- Dr. John Powderly II, MD is an oncologist in Huntersville, North Carolina. He is currently licensed to practice medicine in North Carolina and Texas. He is affiliated with Novant Health Presbyterian Medical Center and is an Assistant Consulting Professor in the Department of Medicine at Duke University School of Medicine.
Education & Training
University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2000 - 2002
University of Texas Health Science Center at HoustonResidency, Internal Medicine/Pediatrics, 1995 - 1999
Georgetown University School of MedicineClass of 1995
Certifications & Licensure
NC State Medical License 2000 - 2025
TX State Medical License 1997 - 2001
Clinical Trials
- A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure
- A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells. Start of enrollment: 2007 Nov 01
- A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) Start of enrollment: 2017 May 02
Publications & Presentations
PubMed
- Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors.Matthew H Taylor, Aung Naing, John Powderly, Paul Woodard, Luke Chung
Journal for Immunotherapy of Cancer. 2024-11-20 - 2 citationsFirst-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas B Karasic, Oxana V Crysler
Cancer Research Communications. 2024-04-18 - First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 ...Toshio Shimizu, John Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D Miller
Frontiers in Oncology. 2024-01-01
Press Mentions
Tempest Therapeutics' Oncology Programs Presented at Society of Immunotherapy for Cancer Annual MeetingNovember 8th, 2019
Community Practices Say Moonshot May SputterMarch 4th, 2016
Professional Memberships
- Member
